Status:
TERMINATED
Non-Invasive Prediction of Colorectal Neoplasia
Lead Sponsor:
Corporal Michael J. Crescenz VA Medical Center
Conditions:
Colonic Polyps
Polyposis Coli
Eligibility:
All Genders
18-85 years
Brief Summary
Hypothesis:The Adnab-9 antigen is a predictive biomarker in individuals at risk of developing colorectal neoplasia. Study aim is to evaluate the potential of the Adnab-9 monoclonal antibody (MAb) as ...
Detailed Description
The primary objectives is to test the efficacy of Adnab-9 stool testing in a population at high-risk for colorectal neoplasia and directly compare it to that of the FOBT and secondarily, identify the ...
Eligibility Criteria
Inclusion
- ability to complete a consent form
- must be at above average risk for colorectal neoplasia
- physically able to undergo colonoscopy or barium enema
Exclusion
- Mentally handicapped
- Physically infirm
- Low risk for colorectal neoplasia
- Pregnant individuals
- Vulnerable populations
Key Trial Info
Start Date :
August 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
2282 Patients enrolled
Trial Details
Trial ID
NCT01815463
Start Date
August 1 2006
End Date
August 1 2014
Last Update
September 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Philadelphia VAMC
Philadelphia, Pennsylvania, United States, 19104